A double-blind study using Canakinumab in Hereditary Periodic Fevers

• Research type

  Research Study

• Full title

  A randomised, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomised withdrawal/ dosing frequency reduction and open-label long term treatment epochs

• IRAS ID

  150033

• Contact name

  Paul Brogan

• Contact email

  p.brogan@ucl.ac.uk

• Eudract number

  2013-004291-35

• Clinicaltrials.gov Identifier

  NCT02059291

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  14/LO/0551

• Date of REC Opinion

  17 Jun 2014

• REC opinion

  Further Information Favourable Opinion